Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 231

1.

Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy.

Zehntner S, Townsend W, Parkes J, Schmidt C, Down M, Bell J, Mulligan R, O'Rourke M, Ellem K, Thomas R.

Pathology. 1999 May;31(2):116-22. Erratum in: Pathology 2000 Feb;32(1):following 64.

PMID:
10399166
2.
3.

Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells.

Nasi ML, Lieberman P, Busam KJ, Prieto V, Panageas KS, Lewis JJ, Houghton AN, Chapman PB.

Cytokines Cell Mol Ther. 1999 Sep;5(3):139-44.

PMID:
10641571
4.
5.

Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.

Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J.

J Immunother. 2006 Sep-Oct;29(5):545-57.

PMID:
16971810
6.
7.

Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma.

van Houdt IS, Oudejans JJ, van den Eertwegh AJ, Baars A, Vos W, Bladergroen BA, Rimoldi D, Muris JJ, Hooijberg E, Gundy CM, Meijer CJ, Kummer JA.

Clin Cancer Res. 2005 Sep 1;11(17):6400-7.

8.
9.

Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor.

Ladányi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A, Gaudi I, Tímár J.

Cancer Immunol Immunother. 2007 Sep;56(9):1459-69. Epub 2007 Feb 6.

PMID:
17279413
10.

Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.

de Gast GC, Klümpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH.

Clin Cancer Res. 2000 Apr;6(4):1267-72.

11.

Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma.

Ridolfi L, Ridolfi R.

Hepatogastroenterology. 2002 Mar-Apr;49(44):335-9.

PMID:
11995445
12.

Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine.

O'Rourke MG, Johnson M, Lanagan C, See J, Yang J, Bell JR, Slater GJ, Kerr BM, Crowe B, Purdie DM, Elliott SL, Ellem KA, Schmidt CW.

Cancer Immunol Immunother. 2003 Jun;52(6):387-95. Epub 2003 Apr 8.

PMID:
12682787
13.
14.

Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene.

Kusumoto M, Umeda S, Ikubo A, Aoki Y, Tawfik O, Oben R, Williamson S, Jewell W, Suzuki T.

Cancer Immunol Immunother. 2001 Sep;50(7):373-81.

PMID:
11676397
15.

Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor.

Shetye J, Ragnhammar P, Liljefors M, Christensson B, Frödin JE, Biberfeld P, Mellstedt H.

Clin Cancer Res. 1998 Aug;4(8):1921-9.

16.

Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma.

Marshall JA, Forster TH, Purdie DM, Lanagan CM, O'Connor LE, O'Rourke MG, Johnson MK, See JL, Ellem KA, Martinez NR, López JA, Schmidt CW.

Immunol Cell Biol. 2006 Jun;84(3):295-302.

PMID:
16681827
17.

T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma.

Ladányi A, Somlai B, Gilde K, Fejös Z, Gaudi I, Tímár J.

Clin Cancer Res. 2004 Jan 15;10(2):521-30.

18.

Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen.

Smithers M, O'Connell K, MacFadyen S, Chambers M, Greenwood K, Boyce A, Abdul-Jabbar I, Barker K, Grimmett K, Walpole E, Thomas R.

Cancer Immunol Immunother. 2003 Jan;52(1):41-52. Epub 2002 Nov 13.

PMID:
12536239
19.

Tumor-specific CD8+ T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content.

Vuylsteke RJ, Molenkamp BG, van Leeuwen PA, Meijer S, Wijnands PG, Haanen JB, Scheper RJ, de Gruijl TD.

Clin Cancer Res. 2006 May 1;12(9):2826-33.

20.

Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L.

J Clin Oncol. 2007 Jun 20;25(18):2546-53.

PMID:
17577033

Supplemental Content

Support Center